Home > News > Foreword – European Endocrinology, 2016;12(2):75
General Endocrinology
Read Time: 2 mins

Foreword – European Endocrinology, 2016;12(2):75

Published Online: September 1st 2016 European Endocrinology, 2016;12(2):75
Authors: Baptist Gallwitz
Quick Links:
Article
Article Information
Article:

Welcome to the latest edition of European Endocrinology, which features a range of insightful articles covering several areas of endocrinology. In recent years, a key requirement of clinical trials investigating new antidiabetes agents has been to demonstrate cardiovascular safety. An editorial by Kalra discusses the findings of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results – A Long Term Evaluation) trial and its potential impact on clinical practice for treating type 2 diabetes.

Despite the increasing use of new antidiabetic agents, insulin remains the cornerstone of diabetes therapy, and patch pumps represent a novel means of insulin delivery, especially for patients with type 1 diabetes. An original research report by Bower and Allender investigates the comparative pulse accuracy of two patch pumps. The study concludes that the accuracy and precision of patch pumps varies and depends on the pumping mechanisms employed. In addition, Nambam and Haller present a review of the latest advances in immunotherapy for type 1 diabetes.

Another original research study performed by Branovan et al. describes the morphological evaluation of the effectiveness of bipolar radiofrequency ablation for thyroid nodules. While radiofrequency ablation is becoming an increasingly popular treatment option for benign thyroid nodules, there is a lack of efficacy and safety data in support of its use.

This issue features two articles on the subject of hypothyroidism. Sorisky discusses subclinical hypothyroidism and the factors underlying its association with cardiovascular disease. In addition, Jacob reviews current strategies for neonatal screening for congenital hypothyroidism, as well as levothyroxine replacement therapy. Finally, Rodriguez-Velver et al. present a fascinating case of a tumour-induced osteomalacia, a rare paraneoplastic syndrome, which developed secondary to a sarcoma.

European Endocrinology would like to thank all expert authors who contributed towards this edition. A special thanks goes to our Editorial Board for their continuing support and guidance. We hope that you will find plenty of interest among these articles.

Article Information:

Further Resources

Share this Article
Related Content In General Endocrinology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72